Hôpital Cochin

Running trials

• Not yet recruiting

  Obinutuzumab in Systemic Sclerosis

  NCT07842523· Phase 2· Source

• Not yet recruiting

  A Clinical Study on Systemic Sclerosis and the Validation of French-language Questionnaires Assessing Disability, Quality of Life, and Disease Status.

  NCT07888842· Source

• Not yet recruiting

  Small Airway Dysfunction in Rheumatoid Arthritis and Systemic Sclerosis

  NCT07924124· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Source

• Not yet recruiting

  Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung Disease

  NCT07827742· Phase 2· Source

• Not yet recruiting

  Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy

  NCT07547033· Source

• Not yet recruiting

  An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy

  NCT07705568· Phase 2· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Source

• Recruiting

  "Translating Articular Biomarkers Into Diagnoses"

  NCT06312943· Source

• Recruiting

  Implementing Low-dose ct Lung Cancer Screening in France.

  NCT07513818· Source

• Recruiting

  Prospective Dynamic Cohort Study of Phenotypic Profiles in Patients With Chronic Obstructive Pulmonary Disease

  NCT07627763· Source

• Recruiting

  Cognition and Patients With Lung Cancer

  NCT07160751· Source

• Not yet recruiting

  Study of Endometrial Immune and Microbiological Modifications in Cases of Recurrent Implantation Failure and/or Recurrent Pregnancy Loss

  NCT07265505· Source

• Recruiting

  Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock

  NCT07345559· Source

• Recruiting

  Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

  NCT06937905· Phase 3· Source

• Recruiting

  Home Treatment of Patients With Active Cancer and Acute Pulmonary Embolism Without HESTIA Criteria.

  NCT07315347· Source

• Not yet recruiting

  " Development of Primary Cultures of Diaphragmatic Myoblasts for Basic Research Purposes "

  NCT07380308· Source

• Recruiting

  Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

  NCT06990659· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or who Cannot Tolerate TNF and/or JAK Inhibitors

  2025-521034-28-00· Phase 2· Source

• Recruiting

  StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis

  NCT06767150· Phase 4· Source

• Recruiting

  Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients

  NCT06133426· Source

• Not yet recruiting

  Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer

  NCT06999512· Phase 2/3· Source

• Recruiting

  A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

  NCT06570798· Phase 2· Source

• Recruiting

  Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

  NCT06878664· Phase 3· Source

• Recruiting

  Involvement of General Practitioners in Lung Cancer Screening

  NCT06956040· Source

• Not yet recruiting

  Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

  NCT06931704· Phase 2· Source

• Recruiting

  Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

  NCT06487078· Source

• Recruiting

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· Phase 3· Source

• Recruiting

  Precision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD

  NCT06582199· Source

• Recruiting

  Medico-economic Evaluation of Robot-assisted Laparoscopy Compared With Conventional Laparoscopy in Hysterectomy for Endometrial Cancer.

  NCT06348719· Source

• Recruiting

  Effects of Yoga Therapy in Rehabilitation Compared to Physiotherapy in Moderate Axial Spondyloarthritis (axSPA)

  NCT06083090· Source

• Recruiting

  Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms

  2024-515362-13-00· Phase 2/3· Source

• Recruiting

  Diagnostic and Prognostic Markers of Endometriosis in Menstrual Blood

  NCT06245512· Source

• Recruiting

  Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

  NCT06476184· Phase 3· Source

• Recruiting

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· Phase 3· Source

• Recruiting

  A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.

  2024-511309-47-00· Phase 2· Source

• Recruiting

  Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer

  NCT06712472· Phase 3· Source

• Recruiting

  FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and platinum as first line treatment in patients with large-cell neuroendocrine carcinomas (LCNECs) of the lung.

  2023-506590-35-00· Phase 2· Source

• Recruiting

  FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

  NCT06393816· Phase 2· Source

• Recruiting

  Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer

  NCT06553612· Source

• Recruiting

  A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

  NCT05980806· Phase 2· Source

• Recruiting

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· Phase 3· Source

• Recruiting

  Fetal Cell Receptors Repertoire

  NCT06031714· Source

• Recruiting

  A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

  NCT06053099· Source

• Recruiting

  Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

  NCT06247826· Source

• Recruiting

  EWALL-PH OBSERVARTORY 2022

  NCT07684131· Source

• Recruiting

  ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases

  NCT05787197· Source

• Active, not recruiting

  Evaluation of an Early Radiomic Signature in Patients With Metastatic Pancreatic Adenocarcinoma Treated With First-line Chemotherapy

  NCT07243288· Source

• Recruiting

  PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

  NCT05581121· Phase 3· Source

• Active, not recruiting

  Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)

  NCT05768711· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer13 recruiting
• Neuroendocrine tumours5 recruiting
• Rheumatoid arthritis5 recruiting
• Systemic sclerosis (scleroderma)5 recruiting
• Childhood cancers4 recruiting
• Liver and biliary tract cancer4 recruiting
• Sarcoma4 recruiting
• COPD3 recruiting
• Endometrial cancer3 recruiting
• Endometriosis3 recruiting
• Multiple myeloma3 recruiting
• Ankylosing spondylitis2 recruiting
• Colorectal cancer2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Osteoporosis2 recruiting
• Ovarian cancer2 recruiting
• Pancreatic cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Alzheimer disease1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Cervical cancer1 recruiting
• Coronary artery disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Hepatitis B1 recruiting
• Lupus (SLE)1 recruiting
• Macular degeneration1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Avoidant and Restrictive Food Intake Disorders (ARFID) in Adolescence: Early Oral Development, Psychopathological Profile and Sensory Integration

  NCT06665802· Source

• Completed

  A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis

  NCT06478706· Phase 2· Source

• Completed

  Personalized Home Respiratory Rehabilitation Program for Subjects With Systemic Sclerosis With Early Lung Disease

  NCT05533034· Source

• Withdrawn

  Comparison of the Effectiveness of a Web Fracture Liaison Service (e_FLS) to Fracture Liaison Services in France: the evAB Study (evAB)

  NCT05303350· Source

• Completed

  Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

  NCT06660147· Source

• Terminated

  Study of ART0380 in Patients With Biologically Selected Solid Tumors

  NCT05798611· Phase 2· Source

• Completed

  A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

  NCT05775289· Phase 2· Source

• Completed

  Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

  NCT05642208· Phase 4· Source

• Completed

  Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease

  NCT05424926· Source

• Completed

  A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

  NCT05560646· Phase 2· Source

• Completed

  Phenotyping of Chronic Pain in Diffused Systemic Scleroderma

  NCT05622578· Source

• Completed

  Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)

  NCT05308966· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Source

• Terminated

  GEN1047 for Solid Tumors - First in Human (FIH) Trial

  NCT05180474· Phase 1/2· Source

• Completed

  Virtual Management of Rheumatoid Arthritis

  NCT05124782· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Source

• Completed

  Comparison Between Ultra-low-dose Computed Tomography and Lung MRI in Cystic Fibrosis

  NCT04644471· Source

• Completed

  A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

  NCT04822350· Source

• Completed

  Cystic Fibrosis Blood Neutrophils

  NCT04970225· Source

• Completed

  Disability Following Hospitalization in People of Working-age Surviving SARS-CoV-2 Infection - COVID-19

  NCT04724395· Source

• Completed

  Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers

  NCT04842682· Phase 1· Source

• Completed

  Zephyr Etude Post-Inscription (French Registry)

  NCT04517916· Source

• Completed

  A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

  NCT04620330· Phase 2· Source

• Completed

  Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

  NCT04111705· Phase 2· Source

• Terminated

  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

  NCT04365868· Phase 2/3· Source

• Completed

  Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global

  NCT04236609· Source

• Completed

  Simultaneous Portal and Hepatic Vein Versus Portal Vein Embolizations for Hypertrophy of the Future Liver Remnant

  NCT03841305· Phase 2· Source

• Completed

  Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

  NCT03829319· Phase 3· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Source

• Completed

  UTOLA: UTerin OLAparib

  NCT03745950· Phase 2· Source

• Completed

  Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

  NCT03445845· Phase 4· Source

• Completed

  Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

  NCT03598270· Phase 3· Source

• Completed

  Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

  NCT03579394· Source

• Completed

  FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

  NCT03584711· Phase 2· Source

• Completed

  Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.

  NCT03164473· Phase 3· Source

• Completed

  Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis

  NCT03401060· Phase 3· Source

• Completed

  Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer

  NCT03249142· Phase 1/2· Source

• Completed

  Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

  NCT02820857· Phase 2· Source

• Completed

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· Phase 3· Source

• Completed

  ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

  NCT02891824· Phase 3· Source

• Completed

  Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

  NCT02757989· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· Source

• Withdrawn

  Pregnancy and Medically Assisted Conception in Rare Diseases

  NCT02450396· Source

• Completed

  A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT01848561· Source

• Completed

  ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)

  NCT02078427· Source

Trial sites

• APHP - Cochin hospital1 trial
• APHP - Hôpital Cochin5 trials
• APHP - HOPITAL COCHIN - Hématologie1 trial
• AP-HP - Hopital Cochin /ID# 2147820 trials
• AP-HP - Hôpital Cochin - service de Médecine Interne2 trials
• APHP - Hopital Cochin - Service de Pneumologie0 trials
• AP-HP - Hôpital Cochin - service de rhumatologie0 trials
• C06 - Pneumologie - Hôpital Cochin - APHP1 trial
• Center of evaluation and treatment of pain - Cochin hospital - APHP1 trial
• Chu Cochin4 trials
• CHU Cochin (Site 0475)0 trials
• CIC 1417 - Hôpital Cochin1 trial
• CIC Cochin Pasteur, Hopital Cochin0 trials
• Cochin Hospital9 trials
• Cochin hospital, AP-HP1 trial
• Cochin Hospital, Rheumatology department2 trials
• Department of Internal Medicine - Cochin hospital1 trial
• Department of Thoracic Surgery - Cochin Hospital1 trial
• Dermatology unit - Cochin Hospital - APHP1 trial
• Duplicate_AP-HP - Hopital Cochin /ID# 987171 trial
• Hôpital Cochin84 trials
• Hôpital Cochin, AP-HP - Department of Dermatology B1 trial
• Hôpital Cochin - Hematologie et Oncologie Médicale1 trial
• Hopital Cochin - Pulmonology0 trials
• Hopital Cochin Saint Vincent De Paul7 trials
• Hôpital Cochin - Service de pneumologie1 trial
• Hopital Cochin (Site 0140)1 trial
• Hopital Cochin (Site 1002)0 trials
• Hopital Cochin (Site 2070)0 trials
• Hopital Cochin (Site 4203)0 trials
• Hopital Cochin/Unité de Cancerologie1 trial
• Hospital of Cochin (AP-HP)1 trial
• Internal medicine, Cochin hospital, APHP0 trials
• Maison de Solenn, Cochin Hospital1 trial
• Paris - Hôpital Cochin5 trials
• Pneumology Department - Hôpital Cochin1 trial
• Rheumatology Department, Cochin Hospital3 trials
• Service de Gastroentérologie, Hôpital Cochin, APHP1 trial
• Service de Gynécologie Obstétrique II et Médecine de la Reproduction - Cochin Hospital1 trial
• Service de Médecine Physique et de Réadaptation, Hôpital Cochin1 trial
• Service de rééducation fonctionnelle, réadaptation de l'appareil locomoteur et Pathologies du Rachis - Cochin Hospital1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Systemic sclerosis (scleroderma)55 works · 8 trials
• COPD32 works · 6 trials
• Rheumatoid arthritis27 works · 9 trials
• Cystic fibrosis26 works · 4 trials
• Type 1 diabetes22 works · 0 trials
• Lupus (SLE)21 works · 4 trials
• Endometriosis20 works · 5 trials
• Ankylosing spondylitis12 works · 3 trials
• Duchenne muscular dystrophy7 works · 0 trials
• Myelodysplastic syndromes7 works · 1 trials
• ANCA-associated vasculitis6 works · 1 trials